Left Atrial Appendage (LAA) Closure Device

• The device is inserted via a catheter through a vein in the groin and navigated to the heart.
• The device is positioned at the opening of the LAA. It typically consists of a mesh-like structure that seals off the appendage.
• Once in place, the device expands to fit snugly and seal the LAA, preventing blood flow into the appendage.
• Over time, tissue grows over the device, permanently sealing off the LAA.

• Patients with non-valvular AFib, particularly those at high risk of stroke but who are unable to take long-term oral anticoagulants due to a high risk of bleeding
• Patients who have had major bleeding events or have a high risk of bleeding, making long-term anticoagulant therapy unsuitable
• Patients with a history of strokes or transient ischemic attacks despite being on anticoagulation therapy
• Patients who prefer a device-based solution over medication

A thorough evaluation by a cardiologist, often including imaging studies and assessment of bleeding risk, is essential to determine if a patient is a suitable candidate for an LAA closure device.

The recovery time after the implantation of a Left Atrial Appendage (LAA) closure device is generally short, but it can vary depending on the individual patient’s health.

• Patients typically stay in the hospital for one to two days following the procedure for monitoring.
• Patients are advised to avoid strenuous activities and heavy lifting for at least a week to 10 days.
• Regular follow-up visits with their cardiologist are necessary to ensure proper healing and device positioning.
• An echocardiogram or other imaging studies may be performed to confirm the device is in place and working as intended.
   

• LAA closure devices significantly reduce the risk of stroke in patients with non-valvular atrial fibrillation, comparable to anticoagulation therapy.
• For patients at high risk of bleeding or those who cannot tolerate anticoagulants, LAA closure devices offer an alternative to long-term medication.
• By avoiding anticoagulants, patients can reduce the risk of major bleeding complications, which is especially beneficial for those with a history of bleeding issues.
• Patients who receive LAA closure devices often experience an improved quality of life since they no longer need regular blood tests and monitoring required with anticoagulant therapy.
• Once implanted, LAA closure devices provide a long-term solution for stroke prevention without the need for ongoing medication adjustments.